Esophageal squamous cell carcinoma (ESCC) accounts for about 90% of esophageal cancer cases and is the sixth most common cause of cancer death worldwide. Targeting cancer stem cells offers a therapeutic approach for addressing cancer, concretely in those cases that are resistant to cisplatin.